Bradmer Pharmaceuticals Inc. (TSE:GLX – Get Free Report) has earned a consensus recommendation of “Strong Buy” from the seven brokerages that are covering the stock, Marketbeat.com reports. One analyst has rated the stock with a hold rating and six have issued a strong buy rating on the company.
Separately, Citizens Jmp raised shares of Bradmer Pharmaceuticals to a “strong-buy” rating in a research report on Tuesday, December 9th.
Get Our Latest Stock Analysis on Bradmer Pharmaceuticals
Bradmer Pharmaceuticals Stock Performance
Featured Stories
- Five stocks we like better than Bradmer Pharmaceuticals
- Elon Taking SpaceX Public! $100 Pre-IPO Opportunity!
- Do not delete, read immediately
- This stock gets a 94 out of 100
- Ticker Revealed: Pre-IPO Access to “Next Elon Musk” Company
- How the Rich Retire
Receive News & Ratings for Bradmer Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bradmer Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
